| abstract |
The present invention includes unique, isolated monoclonal antibodies that bind the PSI domain of human RON (RON PSI ), and methods for making and using the same and novel combination therapies of anti-RON PSI antibodies, including humanized anti-RON PSI antibodies, nucleic acids that encode the heavy chain, the light chain, or both the light and heave chains of the antibody, host cells, expression vectors, and wherein the antibody or binding fragments thereof can be further conjugated with one or more cytotoxic or chemotherapeutic agents. |